Diurnal rhythm of cholesterol biosynthesis in experimental chronic renal failure

被引:9
作者
Chmielewski, M
Nieweglowski, T
Swierczynski, J
Rutkowski, B
Boguslawski, W
机构
[1] Med Univ Gdansk, Dept Chem, PL-80211 Gdansk, Poland
[2] Med Univ Gdansk, Dept Nephrol, PL-80211 Gdansk, Poland
[3] Med Univ Gdansk, Dept Biochem, PL-80211 Gdansk, Poland
关键词
cholesterol biosynthesis; hypercholesterolemia; chronic renal failure; mevalonate; HMG-CoA reductase;
D O I
10.1023/A:1013395921241
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Changes in lipid metabolism are an important risk factor for vascular complications during chronic renal failure (CRF). In experimental CRF hypercholesterolemia has been found to be the main lipid disorder. It is probably due to enhanced cholesterologenesis. Mechanisms of these changes remain poorly understood. It is well known that activity of cholesterologenesis undergoes a significant diurnal rhythm. However, there was no evidence that this rhythm is still present in the course of experimental CRF. Results of our studies indicate that in contrast to puromycin induced nephrotic syndrome, diurnal rhythm of cholesterologenesis in CRF rats is preserved both in liver and in the intestine tissue. Significant higher incorporation of tritiated water into cholesterol fraction was found in vivo both in liver as well as in intestine of CRF rats, as compared to control animals. Increased (with comparison to the controls) incorporation of C-14-acetate, and H-3-mevalonate into CRF rat liver sterols indicate that mechanism of enhanced cholesterologenesis is more complex than simply due to the elevated level of mevalonate (potential substrate for cholesterologenesis) which has been reported in plasma of CRF animals.
引用
收藏
页码:33 / 37
页数:5
相关论文
共 19 条
[11]   PARTIAL REMISSION OF NEPHROTIC SYNDROME IN PATIENT ON LONG-TERM SIMVASTATIN [J].
RABELINK, AJ ;
HENE, RJ ;
ERKELENS, DW ;
JOLES, JA ;
KOOMANS, HA .
LANCET, 1990, 335 (8696) :1045-1046
[12]   The mevalonate pathway and renal diseases: experimental and clinical implications [J].
Scoppola, A ;
Galiano, F .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1998, 21 (05) :243-246
[13]   Plasma mevalonate concentrations in uremic patients [J].
Scoppola, A ;
DePaolis, P ;
Menzinger, G ;
Lala, A ;
DiGiulio, S .
KIDNEY INTERNATIONAL, 1997, 51 (03) :908-912
[14]   DECREASED ALBUMINURIA BY PRAVASTATIN IN HYPERLIPIDEMIC DIABETICS [J].
SHOJI, T ;
NISHIZAWA, Y ;
TOYOKAWA, A ;
KAWAGISHI, T ;
OKUNO, Y ;
MORII, H .
NEPHRON, 1991, 59 (04) :664-665
[15]  
SPERRY WM, 1950, J BIOL CHEM, V187, P97
[16]  
Swierczynski J, 2001, EXP NEPHROL, V9, P54
[17]  
SZOLKIEWICZ M, 1998, WIEN KLIN WOCHENS S4, V110, P45
[18]   STUDIES OF ALTERATION OF HEPATIC CHOLESTEROL-METABOLISM IN PUROMYCIN-INDUCED NEPHROTIC SYNDROME IN RATS [J].
THABET, MAEH ;
CHALLA, A ;
CHAN, JCM ;
PANDAK, WM ;
HEUMAN, DM ;
VLAHCEVIC, ZR .
KIDNEY INTERNATIONAL, 1993, 44 (04) :789-794
[19]   Down-regulation of VLDL receptor expression in chronic experimental renal failure [J].
Vaziri, ND ;
Liang, KH .
KIDNEY INTERNATIONAL, 1997, 51 (03) :913-919